Technologies

Diagnostic Assays : Immune status

Technologies

Field Test for Mycobacterial Infections

A UW–Madison researcher has identified a set of biomarkers that can indicate whether a mammal is vaccinated or infected, as well as the type of infection (bovine tuberculosis or Johne’s disease).
P150020US02

Assay to Determine Risk of Fungal Infection

More specifically, the researchers have developed a detection agent made up of calnexin peptides that recognize the telltale signs of infection. The peptides are able to track how a patient’s helper T cells respond to infection and/or vaccination.
P140236US02

Simple Test for Diagnosing Antibody-Mediated Rejection in Patients with a Kidney Transplant

UW-Madison researchers have identified biomarkers that can be used to detect or predict AMR in kidney transplant patients.  Patients whose urine contains a factor called BAFF, which is known to activate B cells, have or are likely to develop AMR.  Additional biomarkers, including other members of the tumor necrosis factor ligand family as well as chemokines, also are useful for monitoring AMR.
P100036US02

Sensitive Assay for Detecting Botulinum Neurotoxin, Neutralizing Antibodies or Inhibitors

UW-Madison researchers have developed a sensitive and specific method of detecting the presence or activity of botulinum neurotoxin, neutralizing antibodies to the toxin or inhibitors of botulinum toxin.  This method may provide a viable alternative to the mouse bioassay. 

To detect neutralizing antibodies or other inhibitors of botulinum toxin, the method involves exposing cultured neuronal cells to the toxin and a test sample.  The cells are incubated to allow active toxin to cleave an endogenous substrate.  Then the cells are harvested and probed to determine how much substrate was cleaved.  The more neutralizing antibodies or other inhibitors there are, the less cleavage is observed as compared to the control. 

To detect the presence of active neurotoxin, the cultured cells are exposed to a test sample and control samples with known amounts of toxin.  The amount of substrate cleavage can be evaluated to determine how much botulinum neurotoxin is present in the test sample as compared to the control samples.
P07412US